Pharmacodynamics of Org 9487 after a bolus dose followed by a continous infusion in healthy patients

1997 ◽  
Vol 14 (Supplement 16) ◽  
pp. 30
Author(s):  
G. A. Dempsey ◽  
I. M. Dods ◽  
J. M. Hunter
Keyword(s):  
Bolus Dose ◽  
Org 9487

Effects of Human Antithrombin III on Mortality and Blood Coagulation Induced in Rabbits by Endotoxin

1984 ◽  
Vol 51 (02) ◽  
pp. 232-235 ◽  
Author(s):  
D C Triantaphyllopoulos
Keyword(s):  
Blood Coagulation ◽  
Bolus Dose ◽  
Antithrombin Iii ◽  
Coagulation Parameters ◽  
E Coli ◽  
At Iii ◽  
Baseline Values

SummaryTwenty-one rabbits were infused with 20μg/kg/hr of E. coli endotoxin for 6 hr. Eight of the animals were preinjected immediately before the infusion of endotoxin, with a bolus dose of human AT III calculated to increase the antithrombin content of the plasma by about 4 units/ml. All eight animals which were preinjected with AT III survived, while 5 of the 13 control rabbits infused with endotoxin alone died. The changes in coagulation parameters from the baseline values, between the 8 control rabbits which survived and the 8 animals which were preinjected with AT III were compared. The concentration of the preinjected human AT III declined significantly faster (P: <0.01) than that of the native rabbit AT III. AT III prevented the decline of F.XII throughout the infusion of the endotoxin. However, the decline in F.V, fibrinogen, prothrombin and platelets was not affected (P: >0.5) by the injection of AT III.

The Anticoagulant Effect of Heparinoid Org 10172 During Haemodialysis: An Objective Assessment

1986 ◽  
Vol 55 (02) ◽  
pp. 271-275 ◽  
Author(s):  
Helen Ireland ◽  
D A Lane ◽  
Angela Flynn ◽  
E Anastassiades ◽  
J R Curtis
Keyword(s):  
Renal Failure ◽  
Bolus Dose ◽  
Bolus Injection ◽  
Objective Assessment ◽  
Factor Xa ◽  
Fibrin Clot ◽  
Natural Origin ◽  
Fibrin Formation ◽  
Single Bolus Injection

SummaryThe heparinoid of natural origin Org 10172 has anti-factor Xa activity but minimal anti-thrombin activity, and little effect upon broad spectrum assays such as the KCCT in vitro. Its anticoagulant effects have been compared to those of commercial heparin in 7 patients undergoing haemodialysis for chronic renal failure. Commercial heparin was administered in a dose (5,000 iu bolus + 1,500 iu/hour continuous iv infusion) previously shown to inhibit fibrin formation during haemodialysis. This produced mean anti-factor Xa levels in plasma between 0.7-1.0 iu/ml and largely suppressed fibrin formation for 5 h dialysis measured as mean FPA levels in plasma. Administration of Org 10172 as a bolus of 1,350 anti-factor Xa u or 2,000-2,400 anti-factor Xa u produced plasma anti-factor Xa levels of less than 0.5 u/ml and allowed fibrin clot and FPA generation during dialysis. Org 10172 administered as a bolus dose of 4,000-4,800 anti-factor Xa u produced mean anti-factor Xa levels of greater than 0.5 u/ml, allowed dialysis of 6 patients for 5 h and appreciably suppressed FPA generation during dialysis, with little effect on the KCCT.It is concluded that the anti-factor Xa activity of Org 10172 may reflect its ability to inhibit fibrin during dialysis and that single bolus injection of Org 10172 may be a useful alternative method of achieving anticoagulation.

Elimination of three doses of gentamicin over three consecutive days using a polyacrylonitrile-derived filter: An in vitro assessment

2021 ◽  
pp. 039139882110322
Author(s):  
Frédéric J Baud ◽  
Vanessa Seif ◽  
Pascal Houzé ◽  
Jean-Herlé Raphalen ◽  
Benoît Pilmis ◽  
...  
Keyword(s):  
Life Span ◽  
Bolus Dose ◽  
Central Compartment ◽  
Daily Session ◽  
Progressive Decrease ◽  
Time Dependency ◽  
Study Results ◽  
In Vitro Assessment ◽  
The Mean

Introduction: Adsorption of gentamicin in a polyacrylonitrile filter was previously evidenced in a session lasting 6 h using the NeckEpur model. We extended the study over three consecutive days to mimic the 72-h life span of a filter. Methods: Prismaflex® monitor and ST150® filter were used in the continuous diafiltration (CDF) mode at a 2.5 L/h flowrate. The daily session started with a 6-h session of CDF. Thereafter, the 5-L central compartment was changed using a bag free of gentamicin to assess gentamicin release over the following 18 h. Experiments were repeated on Day 2 and stopped at the end of the 6-h session of CDF on Day 3. The experiment was performed in duplicate. Results: At a 2.5 L/h diafiltration flowrate, the mean daily clearances of gentamicin were 5.5, 4.0, and 3.3 L/h, respectively. The mean diafiltration and adsorption ratios in the daily elimination of gentamicin were 32/68%, 58/42%, and 88/12%, respectively. During days 1 and 2, the mean amount of gentamicin released from the ST150® filter were 14 and 34 mg, respectively. Conclusion: The pharmacokinetics of gentamicin over 3 days is strongly altered by adsorption in the same filter with a progressive decrease of elimination by adsorption, suggesting saturation of the filter. One limitation of our study results from the mode of administration using a bolus dose instead of an infusion over 30 min. Adsorption adds a clearance to those of diafiltration. The time-dependency of gentamicin clearance precludes using a constant dosage regimen over the filter’s life span.

Bolus dose esmolol for anesthesia: Is there a need?

1990 ◽  
Vol 2 (4) ◽  
pp. 215-220 ◽  
Author(s):  
John B. Leslie
Keyword(s):  
Bolus Dose

scholarly journals Methylene blue improves hemodynamic shock but increases lipoperoxidation in severe acute pancreatitis pig model

2008 ◽  
Vol 23 (suppl 1) ◽  
pp. 8-16 ◽  
Author(s):  
Roberto Ferreira Meirelles Jr ◽  
Reginaldo Ceneviva ◽  
Fernanda Viaro ◽  
Caroline Floreoto Baldo ◽  
Paulo Roberto Barbosa Evora
Keyword(s):  
Methylene Blue ◽  
Acute Pancreatitis ◽  
Bolus Dose ◽  
Serum Amylase ◽  
Tissue Perfusion ◽  
Pancreatic Tissue ◽  
Control Group ◽  
Hemodynamic Pattern ◽  
Study Results ◽  
Over Time

PURPOSE: Study hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP). METHODS: Thirty pigs were equally divided in control group; MB group; AP group; MB previous AP group; and MB after 90 min of induced AP group. MB was given iv in a bolus dose (2mg.kg-1) followed by maintenance dose (2 mg.kg-1.h-1). Hemodynamic parameters were recorded continuously during 180 min by Swan-Ganz catheter. Blood samples were taken every 60 min to determine arterial and venous nitrate, malondialdehyde (MDA) and amylase. Pancreatic tissue was removed for histopathologic study. RESULTS: In AP group MBP and CO decreased over time 33% (p<0.05) and 52% (p<0.05), respectively. In MB previous induced-AP group, there was 70 minutes delay (p<0.05) to decrease MBP and CO. In MB group arterial and venous nitrite decreased (p<0.05) over time. MB infusion increased (p>0.05) serum MDA when associated to AP. After induced AP, MB did not reverse MBP and CO decrease. There was no difference in serum amylase and necro-hemorrhagic findings with MB treatment. CONCLUSIONS: In this taurocholate-induced AP model MB treatment delayed hemodynamic shock and decreases serum nitrate levels but increases serum MDA levels. No volemic replacement was done and it may have been a mitigated factor to a poor tissue perfusion and impairment microcirculation. Further investigations are needed to elucidate MB treatment role during AP treatment.

Changes in QTc associated with a rapid bolus dose of dexmedetomidine in patients receiving TIVA: a retrospective study

2015 ◽  
Vol 25 (12) ◽  
pp. 1287-1293 ◽  
Author(s):  
Matthias Görges ◽  
Simon D. Whyte ◽  
Shubhayan Sanatani ◽  
Joy Dawes ◽  
Carolyne J. Montgomery ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Bolus Dose ◽  
Rapid Bolus

scholarly journals Use of a New Syringe Pump (Springfusor®) for Muscle Relaxant Infusion

1993 ◽  
Vol 21 (4) ◽  
pp. 444-446 ◽  
Author(s):  
C. C. P. Eagle ◽  
D. F. Capes
Keyword(s):  
Muscle Relaxant ◽  
Infusion Rate ◽  
Bolus Dose ◽  
Muscle Relaxants ◽  
Syringe Pump ◽  
Background Infusion ◽  
Continuous Background ◽  
Nominal Rate ◽  
The Mean ◽  
Initial Bolus

A new spring-driven syringe pump (Springfusor 10®, Go Medical Industries, Subiaco, W.A.) was evaluated for infusion of muscle relaxants in 50 surgical cases. After an initial bolus dose, atracurium was given at a rate of 25 to 37.5 mg/hour and vecuronium at a rate of 4 to 6 mg/hour. The mean infusion rate was found to be 4% above the nominal rate of 5 ml/hour and the accuracy in all cases was within ± 20%. The Springfusor was found to be rugged, cheap and easy to use. It lacks dose flexibility but is suitable for continuous background infusion of muscle relaxants during surgery.

Sign in / Sign up

Export Citation Format

Share Document